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Abstract Here, we examine the photophysical properties
of five ruthenium(II) complexes comprising two 4,7-
diphenyl-1,10-phenanthroline (dip) ligands and function-
alized bipyridine (R1bpy-R2, where R1 = H or CH3,
R2 = H, CH3, COO
-,4-[3-(2-nitro-1H-imidazol-1-yl)pro-
pyl] or 1,3-dicyclohexyl-1-carbonyl-urea) towards devel-
opment of luminescence probes for cellular imaging. These
complexes have been shown to interact with albumin and
the formed adducts exhibited up to eightfold increase in the
luminescence quantum yield as well as the average lifetime
of emission. It was demonstrated that they cannot bind to
DNA through the intercalation mode and its luminescence
in the presence of DNA is quenching. Cell viability
experiments indicated that all complexes possess signifi-
cant dose-dependent cytotoxicity (with IC50 5–19 lM) on
4T1 breast cancer cell line and their anti-proliferative
activity correlates very well with their lipophilicity. Cel-
lular uptake was studied by measuring the ruthenium
content in cells using ICP-MS technique. As expected, the
better uptake is directly related to higher lipophilicity of
doubly charged ruthenium complexes while uptake of
monocationic one is much lower in spite of the highest
lipophilicity. Additionally staining properties were asses-
sed using flow cytometry and fluorescence microscopy.
These experiments showed that complex with 1,3-dicy-
clohexyl-1-carbonyl-urea substituent exhibits the best
staining properties in spite of the lowest luminescence
quantum yield in buffered solution (pH 7.4). Our results
point out that both the imaging and cytotoxic properties of
the studied ruthenium complexes are strongly influence by
the level of internalization and protein interaction.
Keywords Ruthenium polypyridyl complexes 
Cytotoxicity  Optical imaging  Luminescence  Protein
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Introduction
Ruthenium polypyridyl complexes have been studied as
structure- and site-specific DNA probes and nucleus
imaging agents in biological systems, since the interaction
of [Ru(bpy)2(dppz)]
2? (bpy: 2,20-bipyridine, dppz: dipyr-
ido[3,2-a:2030-c]phenazine) complexes with DNA through
intercalation revealed significant enhancement of the
luminescent intensity, the so-called ‘‘light switch’’ effect
[1, 2]. Despite high DNA-binding constant ([106 M-1) [3,
4], ruthenium complexes of the type [RuL2(dppz)]
2?
(L = bpy, phen: phenanthroline, dip: 4,7-diphenyl-1,10-
phenanthroline) demonstrate cellular internalization
(staining of cytoplasm) with limited nuclear accumulation
Electronic supplementary material The online version of this
article (doi:10.1007/s00775-014-1187-5) contains supplementary
material, which is available to authorized users.
O. Mazuryk  K. Magiera  M. Brindell (&)
Department of Inorganic Chemistry, Faculty of Chemistry,
Jagiellonian University, Ingardena 3, 30-060 Krakow, Poland
e-mail: brindell@chemia.uj.edu.pl
K. Magiera  B. Rys
Department of Organic Chemistry, Faculty of Chemistry,
Jagiellonian University, Ingardena 3, 30-060 Krakow, Poland
F. Suzenet
Institute of Organic and Analytical Chemistry, University of
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in live cells [5]. One of the possible reasons for this is
impermeability of nucleus membrane of live cells for
ruthenium complexes. For a probe to be selective towards
nucleus, among others it should have a cationic but also
amphipathic character with the logarithm of water–octanol
partition coefficient (log Po/w) in the range -5 to 0 to
facilitate crossing both cellular and nucleus membranes,
high base strength (pKa [ 10) to exclude localization in
lysosome and finally a planar aromatic system for inter-
calation [6]. Some researchers have tried to optimize the
polypyridyl ligands to reach selective accumulation in
cellular DNA, e.g., by modification of dppz ligand with a
nuclear targeting peptide chain [7–9] or with substituents
increasing its hydrophobicity [2]. Recently the develop-
ment of the ruthenium complexes toward their application
in optical imaging of cells in hypoxia [10, 11] or as cyto-
toxic agents selectively activated in hypoxic cells [12]
shows a new direction in design and great potency of this
type of compounds. One of the most interesting research
aspects is a dual imaging and therapeutic application of
ruthenium polypyridyl complexes [10, 11, 13]. In this
context an appropriate modification of polypyridyl ligands
through the introduction of different substituents can tune
cytotoxic and luminescent properties of ruthenium
complexes.
The principal purpose of the present study is to show the
multifaceted relationship between lipophilicity, protein
interaction and luminescence properties of ruthenium(II)
complexes affecting cell imaging and cytotoxic properties.
The system chosen for this study as illustrated in
Scheme 1, is the family of the ruthenium(II) complexes
comprising two dip ligands and one bpy ligand, which, in





?(at pH [ 5 the carboxylic
group is deprotonated) are well known from the literature
[14], we have recently published the synthesis of
[Ru(dip)2(bpy-NitroIm)]
2? [11] while the formation of
[Ru(dip)2(CH3bpy-DCU)]
2? is described in this work.
These complexes have gained our attention since they are
not expected to have intercalative properties as confirmed
by previous work [11, 15] and these studies, therefore the
cellular DNA is not postulated as their target. Moreover,
the ‘‘light switch’’ effect in the presence of the DNA is not
observed. This is in contrast to numerous studies for
ruthenium polypyridyl complexes [3, 16–18]. The selected
substituents tune lipophilic and photophysical properties.
To demonstrate the interplay between physicochemical/
photophysical properties and biological activity, we ana-
lyze the cytotoxicity and uptake of the studied compounds
using 4T1 breast cancer cell line as well as the lumines-
cence emitted by cells arising from ruthenium complex
accumulation. We also show that the luminescence prop-
erties of these ruthenium complexes strongly depend on the
interaction with albumin, which suggests that in cells the






were purchased from Sigma-Aldrich. 4-carboxy-40-methyl-
2,20-bipyridine(CH3bpy-COOH) and 4-[3-(2-nitro-1H-imi-
dazol-1-yl)propyl]-2,20-bipyridine (bpy-NitroIm) were
prepared according to the published procedures [11, 19].
Ruthenium complexes of the type [Ru(dip)2L]Cl2 where L
denotes bpy, CH3bpy-CH3, CH3bpy-COOH or bpy-Ni-
troIm were prepared following the literature procedures
[11, 19]. The purity of the synthesized complexes was




synthesized as follows. To a stirred solution of [Ru(dip)2-













2+: R1 = R2 = H
[Ru(dip)2(CH3bpy-CH3)]
2+: R1 = R2 = CH3 
[Ru(dip)2(CH3bpy-COO)]
+: R1 = CH3, R2 = COO
-
[Ru(dip)2(CH3bpy-DCU)]
2+: R1 = CH3, R2
[Ru(dip)2(bpy-NitroIm)]
2+: R1 = H, R2 = 
Scheme 1 The studied
ruthenium complexes
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(3 ml) with triethylamine (0.15 ml, 1 mmol), solution of
N,N’-dicyclohexylcarbodiimide (16 mg, 0.077 mmol) in dry
CH2Cl2 (2 ml) was added. The mixture was stirred at room
temperature for 48 h and then the solvent was removed under
reduced pressure. The resulting solid was chromatographed
on aluminium oxide using chloroform/methanol (50:1)
solution as the eluent to afford final compound (12 mg,
27 %) as an orange solid. 1H NMR (600 MHz, CDCl3): d
0.95–1.17 (m, 4H), 1.32–1.70 (m, 12H), 1.80 (m, 2H), 2.14
(bd, J 12.0, 2H), 2.63 (s, 3H), 3.33 (m, 1H), 4.31 (tt, J 3.4,
12.1, 1H), 7.42 (dd, J 1.0, 5.8, 1H), 7.49–7.62 (m, 1H), 7.65
(d, J 5.5, 1H), 7.71 (m, 3H), 7.75 (dd, J 1.6, 5.8, 1H), 7.78 (d,
J 5.5, 1H), 7.88 (d, J 5.4, 1H), 7.95 (d, J 5.5, 1H), 8.07 (d, J
5.9, 1H), 8.09 (d, J 5.5, 1H), 8.16–8.25 (m, 4H), 8.30 (d, J
5.4, 1H), 8.48 (d, J 5.5, 1H), 8.77 (d, J 5.6, 1H), 9.00 (s, 1H),
9.30 (s, 1H), 9.49 (d, J 8.1, 1H) ppm. 13C NMR (150 MHz,
CDCl3): d 21.42, 25.05, 25.16, 25.46, 26.01, 30.71, 31.04,
31.45, 31.64, 50.96, 55.35, 123.11, 125.75, 125.84, 126.21,
126.38, 126.40, 126.64, 126.91, 127.45, 127.84, 128.75,
128.88, 128.90, 129.06, 129.12, 129.23, 129.28, 129.39,
129.64, 129.70, 129.74, 129.78, 129.97, 130.03, 135.23,
135.31, 135.37, 135.44, 146.12, 147.62, 147.98, 148.54,
148.58, 149.01, 149.30, 149.34, 149.55, 150.91, 151.09,
151.15, 151.41, 151.92, 152.73, 153.71, 154.18, 155.97,
157.41, 164.70 ppm. HRMS: calcd. for C73H64N8O2Ru
[M2?] 593.2058, found 593.2092 (Fig. S1A). IR-ATR:
3354w, 3194w, 3054w, 2928m, 2853w, 2157w, 1971w,
1689m, 1649s, 1621s, 1533m. HPLC: tR = 6.96 min, HI-
LIC, acetonitrile/ammonium acetate (0.1 M), gradient from
95:5 to 1:1 (Fig. S1B).
Spectroscopic measurements
UV–Vis absorption spectra were recorded on a Perkin
Elmer Lambda 35 spectrophotometer. Luminescence
measurements were performed on a spectrofluorimeter
Perkin Elmer LS55. The spectra were recorded at the room
temperature in aqueous solution containing small amount
of DMSO (\0.008 % v/v). The emission spectra were
recorded between 470 and 860 nm upon excitation at
463 nm. The average of three scans was subjected to
smoothing. For determination of the quantum yield of
luminescence (U), aqueous solutions of [Ru(bpy)3]
2? with
a small amount of DMSO (\0.008 % v/v) were used as
standards (U = 0.028 [14] and 0.042 [20] for air-equilib-
rium and deoxygenated conditions, respectively). The
spectra were recorded for ruthenium complexes at the
concentration less than 0.05 absorbance unit at the exci-
tation wavelength. Values were calculated according to the
following equation [21]:
U ¼ Uref  Aref=A½   I=Iref½   n2=n2ref
 
;
where I is the integrated intensity of luminescence, A is the
optical density, and n is the refractive index, ref refers to
the values for reference. The mean value from minimum
three independent experiments was calculated.
The luminescence lifetime measurements were per-
formed with a single photon counting technique using
Fluorolog-3, Horiba Jobin Yvon. The excitation wave-
length was set at 464 nm (NanoLed Diodes) and the
average lifetime of luminescence was monitored at
621 nm. Luminescence decays were collected with 1,000
counts in the peak. The instrument response functions were
measured using a light scattering solution of Ludox (col-
loidal silica, Sigma-Aldrich). Experiments were conducted
at room temperature. The DAS6 software (HORIBA Sci-
entific) was used for deconvolution of the obtained decays
and for calculation of the lifetime values. The quality of the
fit was judged by the v2 parameter (the goodness of fit
evaluation). One-exponential fit was determined to be an
optimal description of the obtained results for the ruthe-
nium compounds.
Protein-binding experiments
The protein stock solution was prepared by dissolving
human serum albumin (HSA) in water and its concentra-
tion was determined spectrophotometrically from the molar
absorptivity of 4.4 9 104 cm-1 M-1 at 280 nm [22–25].
The emission spectra were recorded between 305 and
500 nm upon excitation at 295 nm resulting in selective
excitation of tryptophan residue of HSA. The average of
three scans was subjected to smoothing and the fluores-
cence intensities were corrected due to dilution effects.
Protein-binding experiments were conducted by measuring
fluorescence spectra of protein solution (1 lM) in the
presence of different amounts of ruthenium compounds
(0–10 lM) in PBS buffer pH 7.4 at 37 C. Ru–protein
solutions were allowed to incubate for 5 min before the
emission spectra were recorded. The quantum yield and
lifetime of luminescence for ruthenium complexes in the
present of HSA (1 lM) was measured using the same
procedure as described for ruthenium complexes alone (the
HSA/Ru-complex ratio is given in the figure caption).
DNA-binding experiments
Calf thymus deoxyribonucleic acid was purchased from
Sigma-Aldrich and its stock solution was prepared by
dissolving of solid DNA in water. DNA concentrations per
nucleotide were determined by absorption spectroscopy
using the molar absorption coefficient of 6,600 M-1cm-1
at the wavelength of 260 nm [4]. DNA-binding experi-
ments were performed in 0.05 M Tris/HCl buffer (pH 7.4)
J Biol Inorg Chem (2014) 19:1305–1316 1307
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at 37 C. The absorption titration experiments were per-
formed by using fixed concentration of ruthenium com-
pound (10 lM) until the absorption spectra did not change
with increasing DNA concentration. Ruthenium–DNA
solutions were allowed to incubate for 5 min before the
spectra were recorded. The intrinsic DNA-binding constant






Kb eb  efð Þ
;
where [DNA] is the total DNA concentration in nucleo-
tides, ea, eb, ef are the apparent absorption coefficients of
A/[ruthenium complex] of the MLCT absorption band at a
given DNA concentration, fully bound and free ruthenium
complex, respectively, Kb is binding constant.
The emission titration studies were performed by using
fixed concentration of ruthenium compound (3 lM). The
DNA aliquots were added and after 5 min of incubation
luminescence spectra upon excitation at 463 nm were
measured. The average of three scans was subjected to
smoothing and the luminescence intensities were corrected
due to dilution effects.
Determination of lipophilicity
The lipophilicity of the ruthenium(II) complexes, which is
referred to log Po/w (n-octan-1-ol/water partition coeffi-
cient), was measured as following. Ruthenium complexes
were dissolved in n-octan-1-ol (to mM concentration), then
solutions were added to water and the mixtures were stirred
sufficiently for partitioning at 25 C for 24 h. After that the
mixtures were left for equilibration for another 2 h. The
concentration of the compounds in the water phase was
measured spectrophotometrically and Po/w value was cal-






where cbeforeoctanol is an initial concentration of ruthenium
complex, cwater denotes final concentration in water [5].
The experiment was conducted in triplicates.
Cell culture, cytotoxicity and apoptosis assays
4T1 breast cancer cell line was cultured in RPMI-1640
(Gibco Invitrogen) with 10 % fetal bovine serum (FBS, the
bovine serum albumin is a major component), 1 % peni-
cillin and streptomycin and 0.2 % fungizone. Cells were
routinely cultured at 37 C in a humidified incubator in
5 % CO2 atmosphere. Cell viability was measured using
Alamar Blue assay. Cells were seeded on 96-well plate
with density of 104 cells per cm2 and cultured for 24 h in
medium with or without 2 % serum. Then cells were
incubated with various concentrations of ruthenium com-
pounds for 24 h in the dark. All used ruthenium complexes
were freshly diluted in DMSO and then added to the
appropriate medium to obtain the applied concentrations.
The final DMSO concentration was kept constant at 0.05 %
(v/v). Next cells were washed with PBS and incubated in
AlamarBlue solution (21 times diluted in PBS) for 3 h.
Alamar Blue test is based on the reduction of blue and non-
fluorescent subtract (resazurin) to a pink and highly fluo-
rescent product (resorufin) by the alive cells. Extract
mechanism of the reduction is still unknown, but it is
postulated that reduction occurs by mitochondrial or
cytoplasmic enzymes, such as NADH dehydrogenase or
diaphorase. It is still not known whether this process occurs
intracellularly, at the plasma membrane surface or just in
the medium as a chemical reaction [26, 27]. The cell via-
bility was quantified at 605 nm using 560 nm excitation
light (VICTOR 3V multilabel plate readers, PerkinElmer).
Experiments were performed in triplicates and each
experiment was performed at least three times to get the
mean values ± standard deviation. The viability was cal-
culated with regard to the untreated cells control. The IC50
values were determined using Hill equation (Origin 9.0)
[28]:
y ¼ y0 þ
y100  y0ð Þ c½ H
IC50½ Hþ c½ H
The apoptosis was investigated using Hoechst 33258
staining method [29, 30]. 4T1 cells were seeded into
96-well plate with a density of 2 9 104 cells per cm2 and
cultured in the full medium for 24 h. The medium was
removed and replaced with medium containing various
concentrations of the ruthenium complexes. Cells were
incubated with compounds for 24 h, then washed with ice-
cold PBS, fixed with formalin (4 %). Cell nuclei were
counterstained with Hoechst 33258 (10 lg/ml in PBS) for
15 min. Cells were then observed and imaged by an
AxioVert 200M fluorescence microscope (Carl Zeiss).
Ruthenium uptake measured by ICP-MS
Cells were seeded on a 6-well plate with a density of
3 9 105 cells per cm2. 24 h after the incubation ruthenium
complexes were added at 2 lM concentration. Cells were
incubated in medium without serum for 24 h. After incu-
bation cells were washed twice with PBS, detached by
trypsin (trypsin/EDTA from Gibco) treatment, diluted in
PBS and counted. Cells were digested in concentrated
nitric acid overnight at room temperature and then diluted
with water. The ruthenium content of the sample was
1308 J Biol Inorg Chem (2014) 19:1305–1316
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determined by the inductively coupled plasma mass spec-
trometry (ICP-MS). Results were calculated as ruthenium
concentration per cell (assuming the average volume of cell
was 1.7 pL [31]).
Ruthenium uptake measured by flow cytometry
4T1 cells were seeded in a 24-well plate with a density of
2 9 105 cells per cm2. 24 h after the seeding Ru(II) com-
pounds were added at 2 lM concentration and incubated
for 24 h in medium with or without serum (2 %). Then
cells were washed with PBS, detached by trypsin treatment
and analyzed by BDLSR cytometer with an excitation
wavelength of 488 nm and an emission wavelength of
575 ± 13 nm. The luminescence intensity of the control
cells in the tested conditions was found to be negligible.
Imaging
4T1 cells were seeded on the black 96-well plate with a
transparent bottom with a density of 104 cells per cm2 24 h
prior the staining. Next cells were incubated with 1 lM
ruthenium complexes in medium with serum (2 %) for
24 h. After incubation cells were washed with PBS and
images were acquired using an AxioVert 200M fluores-
cence microscope (Carl Zeiss). Illumination system Colibri
with 4 LED excitation diodes (365, 470, 530 and 625 nm)
was applied as source of fluorescence and cube filter with
excitation wavelengths 470 and 555 nm, beam splitter
560 nm, emission range 575–640 nm was used.
Results and discussion
Photophysical characterization of the ruthenium(II)
complexes
The absorption spectra of all studied ruthenium compounds
(Fig. S2) possess an arrow and intense band at 278 nm
assigned to a spin allowed 1LC (1p ? p*bpy-R-centered)
transition, the shoulder at 314 nm originating from a 1LC
transition of phenanthroline moiety and two not well sep-
arated bands at 400–500 nm attributed to the spin allowed
1MLCT d ? p* transitions (assignment based on [32]).
The molar absorption coefficients are presented in Table 1.
The attachment of DCU moiety evidently decreases the
intensity of the MLCT and LC bands while the other
substituents at 4 and 40 positions of the pyridine rings only
slightly influence the energy and intensity of these bands.
The studied ruthenium complexes are found to be
luminescent (Fig. S2) and they all express a shift of the
emission maxima toward a longer wavelengths as well as a
significant decrease in the quantum yield of luminescence
with the respect to the parent complex [Ru(dip)2(bpy)]
2?
(compare Table 1). The red shift is consistent with the
withdrawing character of the attached substituents, which
stabilize the lowest unoccupied molecular orbital of the
bpy ligand, leading to a decrease in the energy of the
MLCT level, responsible for the observed luminescence
properties [14]. The reduction of luminescence quantum
yield can be explained by ‘‘energy gap law’’, predicting an
increase of nonradiative transitions for lower and lower
energy gaps between the emitting level and the ground
Table 1 Photophysical properties for the ruthenium(II) complexes in air-equilibrated and deoxygenated aqueous solutions
Absorption Emission (air-equilibrated conditions) Emission (deoxygenated conditions)
kmax [nm] e [M
-1 cm-1] kmax [nm] u s [ns] u s [ls]
[Ru(dip)2(bpy)]
















2?a 278 88,400 621 0.0103 ± 0.0004 810 ± 10 0.0341 ± 0.0004 1.91 ± 0.01
433 19,100
463 19,700
a Data taken from [11]
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state [14]. Also developing a side chain of bpy ligand as in
case of bpy-2-nitroIm and bpy-DCU can cause an
enhancement of the complexes mobility leading to the
increase of the vibration mode of relaxation. This is also
reflected by almost twofold reduction in a luminescence
lifetime for [Ru(dip)2(CH3bpy-DCU)]
2? comparing to the
parent complex. In contrast, for [Ru(dip)2(bpy-NitroIm)]
2?
despite the decrease of the luminescence quantum yield,
the luminescence lifetime increases probably due to inter-
play of the low-lying MLCT emitting levels and higher-
lying nonemissive metal-centered levels [14]. The lumi-
nescence parameters of the tested compounds strongly
depended on molecular oxygen concentration (2–3 times
higher in the deoxygenated solution), since quenching of
the emission can occur by the diffusion-controlled inter-
action and energy transfer between the triplet excited state
of the metal complex and triplet ground state of oxygen.
This opens a possibility for application of ruthenium
complexes as a luminescence probe for the optical imaging
of physiological hypoxia [10]. Only in the case of
[Ru(dip)2(CH3bpy-DCU)]
2? oxygen does not influence
strongly the quantum yield of luminescence, probably
because of the increased complexes mobility and the
vibration mode of relaxation caused by the expand ligand
(bpy-DCU).
Influence of macro-biomolecules on luminescence
parameters of the ruthenium complexes
There has been a growing interest in the investigations of
the interactions between metal complexes and biomole-
cules, since these interactions can alter compounds
stability, distribution and cytotoxicity [33]. Recently, we
have shown that the presence of human serum albumin
(HSA) greatly influences the luminescence parameters of
[Ru(dip)2(bpy-NitroIm)]
2? [11]. Similar effect but less
pronounced (up to twofold enhancement) was observed for
ruthenium complexes with one diimine and two phenathr-
oline ligands with methyl groups substituted on position 3,
4, 7 and 8 [34]. HSA is the most abundant protein in blood
and exerts significant impact on drugs transport and tox-
icity [29], it can also serve as a model for examination of
the interaction between drugs and proteins. Albumin dis-
plays strong emission peak at 356 nm. Fluorescence is
gradually decreased upon addition of ruthenium(II) poly-
pyridyl complexes (as an example see Fig. 1).
The association constants for formation of adducts
between ruthenium complexes and HSA were determined
using spectrofluorimetric method [22, 35] (details are
described in Supplementary Information) and are summa-
rized in Table 2. Association constants for all complexes
were found to be in the range of ca. 105 M-1 suggesting a
moderate interaction between the investigated ruthenium
complexes and albumin. The parent complex [Ru(dip)2(-
bpy)]2? is characterized by the weakest interaction with
albumin, while the attachment of an additional moiety for
bpy ligand increases affinity of the complexes towards
HSA, probably by increasing the lipophilicity or the
hydrophobic surface of the complexes. The exception is
complex with bpy-DCU ligand that is probably too bulky
to achieve efficient binding.
The formation of adducts with albumin directly influ-
ences the luminescence parameters of the ruthenium
complexes. The excitation of ruthenium complexes in the





































Fig. 1 Fluorescence spectra of
HSA in the present of different
amount of [Ru(dip)2(CH3bpy-
DCU)]2?. Insert: the Stern–
Volmer plot showing the
influence of the increasing
concentration of ruthenium
complex on the fluorescence
intensity of HSA at
kem = 358 nm. Experimental
conditions: [HSA] = 1 lM;
[Ru] = 0–10 lM; PBS pH 7.4;
kex = 295 nm, 37 C
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presence of increasing amount of albumin at 463 nm leads
to gradual increase of both the luminescence quantum yield
as well as the average lifetime of emission as shown in
Fig. 2. It is very likely that the interaction of ruthenium
complexes with HSA leads to partial separation of the
substituents attached to bpy ligand from Ru center by
protein scaffold. In this way protein can prevent from
quenching its luminescence by these moieties. Moreover,
the hydrophobic interactions may intensify the observed
emission. One can assume that similar interaction occurs
inside the cells with other proteins and causes the
enhancement of the luminescence of the ruthenium com-
plexes. [Ru(dip)2(CH3bpy-DCU)]
2? exhibits the largest
increase in luminescence parameters upon addition of
HSA: in PBS in the absence of addition u = 0.0076 while
at [HSA]/[Ru] = 1, u = 0.0472. This gives ca. ninefold
increase in quantum yield of luminescence and makes
HSA–[Ru(dip)2(CH3bpy-DCU)]
2? adduct the most lumi-
nescent species among the studied protein–ruthenium
complex adducts. Correspondingly, the luminescence
average lifetime of ruthenium complexes upon addition of
HSA changes in a similar way, showing 2- to 4-fold
increase at [HSA]/[Ru] = 1 (Fig. 2b).
The investigated ruthenium complexes have moderate
DNA-binding constants (see Table 3, for experimental
details see Supporting Information and Fig. S3). The
intercalation of these complexes is not expected since
unlike dppz ligand the dip ligands are too bulky to permit
efficient intercalation or close contact while bpy ligands are
too small to enable significant stacking [15] and the
selected substituents do not influence strongly the binding
properties. The type of interaction between [Ru(dip)2(bpy-
2-nitroIm)]2? and DNA was thoroughly studied elsewhere
[11]. Based on our previous research, we can suggest that
electrostatic interaction and binding through a DNA groove
are responsible for DNA–Ru interaction for tested com-
plexes. The interaction with DNA causes unusual change in
luminescence properties of these complexes (Fig. S4).
Unlike ruthenium ‘‘light switch’’ complexes ([RuL2
(dppz)]2?), after addition of small excess of DNA lumi-
nescence of [Ru(dip)2(R1bpy-R2)]
2?/? complexes decrea-
ses as a result of diffusion quenching by DNA [11].
Interestingly, [Ru(dip)2(CH3bpy-DCU)]
2? does not exhibit
quenching of luminescence, but only small shift towards
lower wavelengths (Fig. S4). It is reasonable to assume,
that its weak luminescence properties arising from an
increased mobility of the complex caused by the attached
expand ligand (bpy-DCU) making it no longer sensitive
toward quenchers like DNA or O2 (Table 1). Higher DNA/
Ru ratio([80 excess of DNA) significantly increases of
ruthenium complexes luminescence intensity (Fig. S4).
This can be explained by reduction of their mobility and
the vibration mode of relaxation, as well as the protection
of the ruthenium complexes from quenching by water
molecules due to the hydrophobic environment inside the
DNA [36].
Lipophilicity of the ruthenium polypyridyl complexes
Lipophilicity is commonly described as the n-octan-1-ol/
water partition coefficient (expressed in log Po/w) of the
compounds, which was determined by a shaking method. It





2? 0.78 ± 0.02
[Ru(dip)2(CH3bpy-CH3)]
2? 1.24 ± 0.06
[Ru(dip)2(CH3bpy-COO)]
? 1.17 ± 0.04
[Ru(dip)2(CH3bpy-DCU)]
2? 0.98 ± 0.03
[Ru(dip)2(bpy-NitroIm)]
2? 1.10 ± 0.06
































Fig. 2 The luminescence quantum yield (a) and the average lifetime
of luminescence (b) of the studied ruthenium complexes for various
[HSA]/[Ru] ratios. Experimental conditions: [HSA] = 1 lM,
[Ru] = 1–3 lM; PBS pH 7.4, excitation at 463 nm
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is well known that lipophilicity of the metal complexes is
critical for their cellular selective uptake: cationic probes
showing uptake in nuclei and lysosomes have -5 \ log Po/w
\ 0, while dyes with 0 \ log Po/w \ 5 accumulate prefer-
entially in mitochondria and endoplasmic reticulum [6].
The log Po/w values of ruthenium(II) polypyridyl complexes
are listed in Table 4. The additional substituents in bpy
ligand increase lipophilicity of the ruthenium complexes.
Among dicationic complexes [Ru(dip)2(CH3bpy-DCU)]
2?
is characterized by the highest log Po/w value arising from
the expanded substituent in bpy ligand, while for
[Ru(dip)2(CH3bpy-COO)]
?the relatively high log Po/w is
caused by monocationic character of the complex. The lit-
erature data have demonstrated that positively charged
ruthenium complexes show higher uptake than neutral one
[15], at the same time monocationic species show higher
uptake compared to the dicationic one [37]. However, the
lipophilicity of the compound outweighs the influence of
the number of positive charges [37]. The cellular uptake is
at least partially controlled by lipophilicity, therefore this
parameter can also influence the cytotoxicity of ruthenium
complexes as well as the intensity of the observed lumi-
nescence signal.
In vitro cytotoxicity
The cytotoxicity of the ruthenium complexes was evalu-
ated using 4T1 breast cancer cell line. Cisplatin was used
as a positive control. Ruthenium complexes can interact
with proteins [34, 38], so cytotoxicity of the complexes
was evaluated both in medium with or without serum. The
IC50 values of the tested complexes are listed in Table 5.
Ruthenium polypyridyl complexes are found to be much
more cytotoxic than cisplatin against 4T1 cell line, ca. one




2? were found to be the most toxic in the studied
conditions. One of the possible explanations is the high
lipophilicity of the former one and moderate liphophilicity
and smaller size of the later one, which should facilitate
their uptake. [Ru(dip)2(CH3bpy-COO)]
? is less cytotoxic
despite the highest lipophilicity, this may be due to its
lower accumulation as confirmed by uptake studies. The
addition of serum containing as a major component bovine
serum albumin to the incubation medium results in ca.
twofold decrease in cytotoxicity (see Table 5). Likely the
formed adducts between the tested ruthenium compounds
and serum proteins are less accessible for the cells. Con-
sequently, ruthenium accumulation may get less efficient.
The range of cytotoxicity reduction correlates with the
values of the protein–Ru association constants (Table 2).
The same cytotoxic order for the studied ruthenium com-
plexes was also found in human lung adenocarcinoma
(A549) cell line as well as in two endothelial cell lines
(murine lung microvascular endothelial and murine endo-
thelial cells from AGM region from 10.5 dpc embryos,
details are presented in Supplementary information and in
Table S1).
In order to clarify how ruthenium complexes affected
cell growth, after treatment with compound cells were
examined by fluorescence microscope. Representative
images are shown in Fig. 3. 4T1 cells after incubation with
ruthenium compounds show marked morphological sign of
apoptosis, such as decreasing amount of detached cells,
cells rounding and shrinkage [39]. To evaluate the nucleus
morphological changes, cells were stained with Hoechst
and analyzed by fluorescence microscopy. The untreated
population of cells displays a homogenous morphology
with round nuclei evenly stained with Hoechst. After
treatment with ruthenium complexes, most of the cells
display fragmented nuclei with densely stained nucleus
granular bodies of chromatin (so-called ‘‘apoptotic





2? 0.82 ± 0.01
[Ru(dip)2(CH3bpy-CH3)]
2? 0.53 ± 0.03
[Ru(dip)2(CH3bpy-COO)]
? 1.05 ± 0.15
[Ru(dip)2(CH3bpy-DCU)]
2? 0.60 ± 0.02
[Ru(dip)2(bpy-NitroIm)]
2? 0.68 ± 0.01




2? 0.328 ± 0.026
[Ru(dip)2(CH3bpy-CH3)]
2? 0.484 ± 0.046
[Ru(dip)2(CH3bpy-COO)]
? 1.857 ± 0.079
[Ru(dip)2(CH3bpy-DCU)]
2? 1.114 ± 0.012
[Ru(dip)2(bpy-NitroIm)]
2? 0.413 ± 0.083
Table 5 The IC50 values of the ruthenium(II) complexes and cis-
platin against 4T1 cell line after 24 h of incubation in medium with or
without serum (2 %)
Without serum With serum
[Ru(dip)2(bpy)]
2? 6.79 ± 1.09 13.56 ± 1.75
[Ru(dip)2(CH3bpy-CH3)]
2? 4.90 ± 0.30 9.32 ± 1.37
[Ru(dip)2(CH3bpy-COO)]
? 8.66 ± 1.47 13.90 ± 3.00
[Ru(dip)2(CH3bpy-DCU)]
2? 4.71 ± 0.18 9.01 ± 1.33
[Ru(dip)2(bpy-NitroIm)]
2? 10.64 ± 1.05 18.78 ± 1.29
Cisplatin 73.00 ± 14.94 59.81 ± 8.32
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bodies’’) [29]. The results suggest that cytotoxic effect of
ruthenium complexes is based at least partially on their
pro-apoptotic properties.
Cellular uptake studies by ICP-MS
To quantify the concentration of ruthenium accumulated
inside the 4T1 cells, the ICP-MS measurements were
used. The uptake was determined for the sub-lethal dose
of ruthenium compounds to evaluate the ability of the
tested complexes to internalize into live cells. The
absolute values of ruthenium concentration found in
cells strongly depend on applied experimental conditions
[40], thus the obtained results shown in Fig. 4 are pre-
sented in relation to [Ru(dip)2(CH3bpy-DCU)]
2? that
exhibits the highest accumulation. The actual values of
the accumulated ruthenium concentration vary from 130
Fig. 3 Effect of the ruthenium
complexes treatment towards
mammary cancer cells. a, c, e:
DIC (differential interferential
contrast), b, d, e: fluorescence
labeling of the nuclei by
Hoechst 33258 of the 4T1 cells


























































Fig. 4 Relative ruthenium accumulation in 4T1 cell line in a single
cell determined by ICP-MS. Experimental conditions: [Ru-com-
plex] = 2 lM, 24 h incubation in the darkness
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to 1,200 lM (Fig. S5) and it correlates with previously
reported ICP-MS measurement of ruthenium complexes
uptake [31]. The rise of the accumulation for dicationic
ruthenium complexes correlates with their increased
lipophilicity. Such relationship has been already reported
[41]. The monocationic [Ru(dip)2(CH3bpy-COO)]
?
expresses much smaller accumulation than the rest of the
studied complexes despite having the highest log Po/w
value. The charge of the compound displays a stronger
influence than lipophilicity on ruthenium accumulation.
This can arise from a possible facilitated transport of
ruthenium polypyridyl complexes into cells via passive
diffusion due to membrane potential [31]. The greater
uptake the higher cytotoxicity suggests that internaliza-
tion of the ruthenium complexes is required for their
biological activity.
Cell luminescence upon treatment by ruthenium
complexes
The uptake of the tested ruthenium complexes by 4T1 cells
was also monitored using flow cytometry (Fig. S6). It must
be noted that the light emission by the cells was not pro-
portional to the amount of ruthenium incorporated inside
cells since the luminescence quantum yield for various
ruthenium complexes is different. Furthermore, the lumi-
nescence of ruthenium complexes is substantially influ-
enced by the interaction with proteins. The observed
luminescence signal (shown in Fig. 5) combines both the
ability of the compounds to cross the cell membrane and
the luminescence intensity emitted after interaction with
cytoplasmic molecules and organelles. This method is
adequate for an evaluation of the cell staining capacity by
ruthenium complexes. [Ru(dip)2(CH3bpy-DCU)]
2? pro-
vided the highest luminescence of 4T1 cells. This complex
is characterized by the smallest quantum yield of lumi-
nescence, but due to its interaction with protein the quan-
tum yield greatly increases and its high lipophilicity
intensifies its uptake. In general, for all the studied com-
plexes the order of luminescence expressed by cells cor-
relates with the cellular uptake determined by ICP-MS
method as well as the cytotoxicity data. When the incu-
bation of ruthenium complexes with cells was carried out
in medium supplemented with serum, the cells expressed
smaller luminescence intensity (see Fig. 5). This further
confirms that the access of the ruthenium complexes to
cells is lower, probably due to formation of adduct with
proteins. Similar results have been obtained for endothelial
MLuMEC cells (Supplementary Information Fig. S7).
Analyzing the staining pattern of live cells for the
studied ruthenium complexes, no significant differences
between each other is found (Fig. 6; Fig. S8), only the
intensity of the staining is altered. This suggests that the
place of accumulation of ruthenium complexes is deter-



















































Fig. 5 Mean luminescence intensity of 4T1 cell lines incubated with
ruthenium compounds measured by flow cytometry (filed incubated
without serum, dashed incubated with serum). Experimental condi-
tions: [Ru-complex] = 2 lM, 24 h of incubation in medium without
or with serum (2 %)




(c) for 24 h
1314 J Biol Inorg Chem (2014) 19:1305–1316
123
complex. Cytoplasm is marked homogeneously with edge
of the nucleus (mitochondria/endoplasmic reticulum)
pointed out. No staining in the nucleus is observed con-
firming no incorporation in the DNA.
Conclusions
We have shown for a series of complexes [Ru(dip)2(R1bpy-
R2)]
2?/? that the higher luminescence parameters measured in
aqueous solution do not directly correspond to the best cell
staining properties. It is a combined effect of the luminescence
expressed in cellular environment and the extent of its accu-
mulation. For all studied complexes the interaction with
human serum albumin results in pronounced increase of
quantum yield and lifetime of luminescence. This phenome-
non can be called ‘‘light switch’’ effect and for the studied
complexes is observed only in the presence of albumin while
DNA induces minor changes in their luminescence. As the
intracellular protein content is high (ca. 50–400 mg/ml) we
can expect that similar effect is taking place. Therefore, while
designing cellular probes it is necessary to take into account
not only the luminescence parameters of a single substance,
but also the possible resulting adducts with biomacro mole-
cules. The [Ru(dip)2(CH3bpy-DCU)]
2? regardless of its
weakest luminescence parameters displays the best staining
properties. Additionally, the lipophilicity and complex charge
determine the level of its uptake which explains its cytotox-
icity and imaging properties. The mechanism of action of
these type of complexes remains still unknown, but our pre-
liminary data point out that they can induce the apoptosis.
Acknowledgments Financial support from the National Science
Center (Grant No. N N204 247340) is acknowledged. The research
was carried out with equipment purchased with financial support from
the European Regional Development Fund within the framework of
the Polish Innovation Economy Operational Program (contract no.
POIG.0 2.01.00-12-0 23/08). O.M. acknowledges the financial sup-
port from the project Interdisciplinary PhD Studies ‘‘Molecular sci-
ences for medicine’’ (co-financed by the European Social Fund within
the Human Capital Operational Programme). The authors gratefully
acknowledge Wiesław Knap for performing the ICP-MS experiments.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Friedman AE, Chambron J-C, Sauvage J-P, Turro NJ, Barton JK
(1990) J Am Chem Soc 112:4960–4962
2. Gill MR, Derrat H, Smythe CGW, Battaglia G, Thomas JA
(2011) Chembiochem 12:877–880
3. Gao F, Chao H, Zhou F, Yuan YX, Peng B, Ji LN (2006) J Inorg
Biochem 100:1487–1494
4. Srishailam A, Kumar YR, Gabra NMD, Reddy PV, Deepika N,
Veerababu N, Satyanarayanna S (2013) J Fluoresc 23:897–908
5. Puckett CA, Barton JK (2007) J Am Chem Soc 129:46–47
6. Horobin RW, Stockert JC, Rashid-Doubell F (2006) Histochem
Cell Biol 126:165–175
7. Puckett CA, Barton JK (2010) Bioorg Med Chem 18:3564–3569
8. Puckett CA, Barton JK (2009) J Am Chem Soc 131:8738–8739
9. Blackmore L, Moriarty R, Dolan C, Adamson K, Forster RJ,
Devocelle M, Keyes TE (2013) Chem Commun 49:2658–2660
10. Komatsu H, Yoshihara K, Yamada H, Kimura Y, Son A, Ni-
shimoto S, Tanabe K (2013) Chem Eur J 19:1971–1977
11. Mazuryk O, Maciuszek M, Stochel G, Suzenet F, Brindell M
(2014) J Inorg Biochem 134:83–91
12. Yadav A, Janaratne T, Krishnan A, Singhal SS, Yadav S, Dayoub
AS, Hawkins DL, Awasthi S, MacDonnell FM (2013) Mol
Cancer Ther 12:643–653
13. Chen Y, Qin M-Y, Wang L, Chao H, Ji L-N, Xu A-L (2013)
Biochimie 95:2050–2059
14. Waern JB, Desmarets C, Chamoreau L, Amouri H, Barbieri A,
Sabatini C, Ventura B, Barigelletti F (2008) Inorg Chem
47:3340–3348
15. Lamoureux M, Seksek O (2010) J Fluoresc 20:631–643
16. Zeglis BM, Pierre VC, Barton JK (2007) Chem Commun
44:4565–4579
17. Tan LF, Shen JL, Chen XJ, Liang XL (2009) DNA Cell Biol
28:461–468
18. Gill MR, Thomas JA (2012) Chem Soc Rev 41:3179–3192
19. Caspar R, Cordier C, Waern JB, Guyard-Duhayon C, Gruselle M,
Le Floch P, Amouri H (2006) Inorg Chem 45:4071–4078
20. Nair RB, Cullum BM, Murphy CJ (1997) Inorg Chem
36:962–965
21. Lakowicz JR (2006) Principles of fluorescence spectroscopy.
Springer, New York
22. Mazuryk O, Niemiec E, Stochel G, Gillaizeau I, Brindell M
(2013) J Lumin 140:51–56
23. Lu X-L, Fan J-J, Liu Y, Hou A-X (2009) J Mol Struct 934:1–8
24. Feroz SR, Mohamad SB, Bakri ZSD, Malek SNA, Tayyab S
(2013) Plos One 8:e76067
25. Carta G, Jungbauer A (2010) Protein chromatography: process
development and scale-up. Wiley-VCH, Federal Republic of
Germany
26. O’Brien J, Wilson I, Orton T, Pognan F (2000) Eur J Biochem
267:5421–5426
27. Borra RC, Lotufo MA, Gagioti SM, Barros FDM, Andrade PM
(2009) Braz Oral Res 23:255–262
28. Weyermann J, Lochmann D, Zimmer A (2005) Int J Pharm
288:369–376
29. Liu Y, Yu Q, Wang C, Sun D, Huang Y, Zhou Y, Liu J (2012)
Inorg. Chem. Comm. 24:104–109
30. Tan C, Hu S, Liu J, Ji L (2011) Eur J Med Chem 46:1555–1563
31. Puckett CA, Barton JK (2008) Biochemistry 47:11711–11716
32. Juris A, Balzani V, Barigelletti F, Campagna S, Belser P, Vo-
nzelewsky A (1988) Coord Chem Rev 84:85–277
33. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P
(2012) Mol Asp Med 33:209–290
34. Rajendiran V, Palaniandavar M, Periasamy VS, Akbarsha MA
(2012) J Inorg Biochem 116:151–162
35. Mazuryk O, Kurpiewska K, Lewinski K, Stochel G, Brindell M
(2012) J Inorg Biochem 116:11–18
36. Sun B, Wang YC, Qian C, Chu J, Liang SM, Chao H, Ji LN
(2010) J Mol Struct 963:153–159
37. Schafer S, Ott I, Gust R, Sheldrick WS (2007) Eur J Inorg Chem
2007:3034–3046
J Biol Inorg Chem (2014) 19:1305–1316 1315
123
38. Mazuryk O, Suzenet F, Kieda C, Brindell M, (2014) in
preparation
39. Chen Y, Lu B, Yang Q, Fearns C, Yates J, Lee JD (2009) Cancer
Res 69:3713–3720
40. Egger AE, Rappel C, Jakupec MA, Hartinger CG, Heffeter P,
Keppler BK (2009) J Anal At Spectrom 24:51–61
41. Yu HJ, Chen Y, Yu L, Hao ZF, Zhou LH (2012) Eur J Med Chem
55:146–154
1316 J Biol Inorg Chem (2014) 19:1305–1316
123
